Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an updated COVID-19 vaccine keep up with the virus?

NCT ID NCT07730450

Vaccine Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This trial is testing an updated version of the BNT162b2 COVID-19 vaccine in healthy adults aged 18 to 64. Participants will receive either the updated COVID-19 vaccine or a Tdap vaccine (for tetanus, diphtheria, and whooping cough) to compare safety and measure spike protein levels in the blood. The study aims to see how well the updated vaccine works and whether it is safe for seasonal use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an updated RNA-based COVID-19 vaccine (BNT162b2) targeting a SARS-CoV-2 variant
What this could lead to
If successful, this could support the use of updated COVID-19 vaccines for seasonal protection in healthy adults.
What could go wrong
This is a phase 4 safety study with only 200 participants, so it may not detect rare side effects or fully predict real-world effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria \- Healthy participants 18 through 64 years of age who do not have medical conditions that put them at a higher risk for severe COVID-19. Key Exclusion Criteria * Participants who tested positive for COVID-19 within 6 months (180 days) prior to Visit 1 * Participants who have recently received a vaccine, or plan to receive a nonstudy COVID-19 or comparator vaccine during participation. The complete list of inclusion and exclusion criteria are listed in the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 vaccines are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease Coronaviridae Infections Infections lung disorder Nidovirales infectious disease pneumonia respiratory system disorder respiratory tract infectious disorder RNA Virus Infections viral infectious disease viral pneumonia COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 vaccines

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Diablo Clinical Research, LLC dba Flourish Research

    RECRUITING

    Walnut Creek, California, 94598, United States

  • Duke Vaccine and Trials Unit

    RECRUITING

    Durham, North Carolina, 27703, United States

  • East-West Medical Research Institute

    RECRUITING

    Honolulu, Hawaii, 96814, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic

    RECRUITING

    Salt Lake City, Utah, 84109, United States

  • Palm Springs Community Health Center

    RECRUITING

    Miami Lakes, Florida, 33014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.